Abstract:Introduction All approved anticoagulants including the direct oral anticoagulants have been associated with an increased risk of bleeding in a dose-dependent manner when used either as monotherapy and/or on top of antiplatelet drugs. Literature reports have suggested that the extrinsic pathway of coagulation is important for haemostasis while the intrinsic pathway of coagulation along with thrombin feedback activation of FXI are primarily responsible for pathological thrombus formation and propagation. Recent clinical trials with several FXI/FXIa inhibitors in development including milvexian (BMS-986177/ JNJ-70033093) have demonstrated robust antithrombic efficacy without any increase in bleeding compared with standard of care in the settings of total knee arthroplasty. Milvexian inhibits FXIa upstream in the intrinsic pathway of coagulation while approved anticoagulants including warfarin, heparin, bivalirudin, and DOACs inhibit FXa and/or thrombin, which are components of the final common pathway of coagulation that lies in the interface of the intrinsic and extrinsic pathways. Purpose To evaluate the impact of milvexian, apixaban and dabigatran on thrombin generation (TG) initiated by the intrinsic vs extrinsic pathway activators in human plasma in vitro. Methods Platelet-poor plasma prepared from citrated whole blood collected from consenting, healthy adult volunteers (n=6) was spiked with 0.1–10 μM milvexian, apixaban, or dabigatran. TG via the extrinsic pathway (5 pM tissue factor, PPP Reagent, Stago) and intrinsic pathway (1:100 dilution of STA®-PTT Automate) was measured using using the Thrombinoscope method (Stago) and included peak thrombin, lag time and the endogenous thrombin potential (ETP). Results All compounds tested demonstrated robust (>70%) to complete inhibition of the ETP initiated by the intrinsic pathway activator (STA®-PTT Automate reagent, Fig. 1A). Apixaban and dabigatran also completely inhibited ETP initiated by the extrinsic pathway activator (PPP Reagent, Fig. 1B). In contrast, milvexian only had a modest inhibition (<20%) of ETP when initiated by the extrinsic pathway activator. Conclusions By inhibiting the final common pathway of coagulation, apixaban and dabigatran inhibit TG initiated via both, intrinsic and extrinsic pathways, in a concentration-dependent manner. In contrast, by inhibiting FXIa upstream in the intrinsic pathway, milvexian predominantly inhibits TG initiated by the intrinsic pathway activator but only has a minimal impact on TG initiated by the extrinsic pathway that is deemed critical for haemostasis. These findings with milvexian are consistent with observations of TG in FXI immunodepleted plasma reported previously by our group (ISTH 2021). The potential haemostasis sparing effect of milvexian and perhaps of other FXI/FXIa inhibitors may explain in part the low rate of bleeding observed to date with this new class of experimental anticoagulant drugs in clinical development. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Janssen Research & Development

Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding

TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1

Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation

Factor Xa or thrombin: is thrombin a better target?

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo

Differential impact of milvexian, an investigational oral FXIa inhibitor vs apixaban and dabigatran on thrombin generation in human donor plasma in vitro

Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists

Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects

Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors

Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system

Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes

Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis

Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors

Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin

Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists

Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances

Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis

Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects